H.C. Wainwright Maintains Collplant(CLGN.US) With Buy Rating, Maintains Target Price $11
CollPlant Biotechnologies Analyst Ratings
H.C. Wainwright Maintains Collplant(CLGN.US) With Buy Rating, Maintains Target Price $11
Buy Rating Affirmed for Collplant Holdings Amid Advancing Biotech Prospects and Promising Financial Outlook
CollPlant Biotechnologies Analyst Ratings
CollPlant Biotechnologies Analyst Ratings
EF Hutton Maintains Collplant(CLGN.US) With Buy Rating, Cuts Target Price to $14
CollPlant Biotechnologies Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Collplant Holdings (CLGN) and Zimmer Biomet Holdings (ZBH)
Buy Rating Affirmed for Collplant Holdings on Strong Financials and Promising Product Pipeline Advancements
CollPlant Biotechnologies Analyst Ratings
Analysts' Top Healthcare Picks: Collplant Holdings (CLGN), UnitedHealth (UNH)
HC Wainwright & Co. Reiterates Buy on CollPlant Biotechnologies, Maintains $11 Price Target
CollPlant Biotechnologies Analyst Ratings
Collplant Holdings (CLGN) Gets a Buy From H.C. Wainwright
HC Wainwright & Co. Reiterates Buy on CollPlant Biotechnologies, Maintains $11 Price Target
CollPlant Biotechnologies Analyst Ratings
H.C. Wainwright Sticks to Their Buy Rating for Collplant Holdings (CLGN)
HC Wainwright Adjusts Price Target on CollPlant Holdings to $11 From $26, Maintains Buy Rating
HC Wainwright & Co. Maintains Buy on CollPlant Biotechnologies, Lowers Price Target to $11